Literature DB >> 32871005

Pathophysiology of atrial fibrillation and chronic kidney disease.

Wern Yew Ding1, Dhiraj Gupta1, Christopher F Wong2, Gregory Y H Lip1,3.   

Abstract

Atrial fibrillation (AF) and chronic kidney disease (CKD) are closely related conditions with shared risk factors. The growing prevalence of both AF and CKD indicates that more patients will suffer from concurrent conditions. There are various complex interlinking mechanisms with important implications for the management of these patients. Furthermore, there is uncertainty regarding the use of oral anticoagulation (OAC) in AF and CKD that is reflected by a lack of consensus between international guidelines. Therefore, the importance of understanding the implications of co-existing AF and CKD should not be underestimated. In this review, we discuss the pathophysiology and association between AF and CKD, including the underlying mechanisms, risk of thrombo-embolic and bleeding complications, influence on stroke management, and evidence surrounding the use of OAC for stroke prevention. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Thromboembolism; Anticoagulation; Atrial fibrillation; Bleeding; Chronic kidney disease; Kidney impairment; NOAC; Pathophysiology; Renal failure; Stroke; VKA; Warfarin

Mesh:

Substances:

Year:  2021        PMID: 32871005     DOI: 10.1093/cvr/cvaa258

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  7 in total

1.  Efficacy and Safety of Oral Anticoagulants for Atrial Fibrillation Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.

Authors:  Tae-Min Rhee; So-Ryoung Lee; Eue-Keun Choi; Seil Oh; Gregory Y H Lip
Journal:  Front Cardiovasc Med       Date:  2022-06-10

Review 2.  The effect of obesity, hypertension, diabetes mellitus, alcohol, and sleep apnea on the risk of atrial fibrillation.

Authors:  Z Čarná; P Osmančík
Journal:  Physiol Res       Date:  2021-12-30       Impact factor: 2.139

Review 3.  Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes.

Authors:  Giuseppe Boriani; Marco Vitolo; Igor Diemberger; Marco Proietti; Anna Chiara Valenti; Vincenzo Livio Malavasi; Gregory Y H Lip
Journal:  Cardiovasc Res       Date:  2021-06-16       Impact factor: 13.081

Review 4.  Interactions Between Kidney Function and Cerebrovascular Disease: Vessel Pathology That Fires Together Wires Together.

Authors:  Sandro Marini; Marios K Georgakis; Christopher D Anderson
Journal:  Front Neurol       Date:  2021-11-24       Impact factor: 4.003

5.  Association of Hyperuricemia with Impaired Left Ventricular Systolic Function in Patients with Atrial Fibrillation and Preserved Kidney Function: Analysis of the POL-AF Registry Cohort.

Authors:  Marcin Wełnicki; Iwona Gorczyca-Głowacka; Arkadiusz Lubas; Wiktor Wójcik; Olga Jelonek; Małgorzata Maciorowska; Beata Uziębło-Życzkowska; Maciej Wójcik; Robert Błaszczyk; Renata Rajtar-Salwa; Tomasz Tokarek; Jacek Bil; Michał Wojewódzki; Anna Szpotowicz; Małgorzata Krzciuk; Monika Gawałko; Agnieszka Kapłon-Cieślicka; Anna Tomaszuk-Kazberuk; Anna Szyszkowska; Janusz Bednarski; Elwira Bakuła-Ostalska; Beata Wożakowska-Kapłon; Artur Mamcarz
Journal:  Int J Environ Res Public Health       Date:  2022-06-14       Impact factor: 4.614

6.  Impact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF Long-Term General Registry.

Authors:  Wern Yew Ding; Tatjana S Potpara; Carina Blomström-Lundqvist; Giuseppe Boriani; Francisco Marin; Laurent Fauchier; Gregory Y H Lip
Journal:  Eur J Clin Invest       Date:  2022-01-17       Impact factor: 5.722

Review 7.  Atrial Fibrillation in Chronic Kidney Disease: An Overview.

Authors:  Sai Gadde; Revanth Kalluru; Swathi Priya Cherukuri; Rahul Chikatimalla; Thejaswi Dasaradhan; Jancy Koneti
Journal:  Cureus       Date:  2022-08-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.